JMP Securities Reiterates Market Outperform, $12 Target on Alexza Pharma (ALXA) After Q2
Tweet Send to a FriendGet Alerts ALXA Hot Sheet
Price: $4.59 +1.77%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ALXA Now!
JMP Securities reiterated their Market Outperform rating and $12 price target on Alexza Pharma (NASDAQ: ALXA) following Q2 results.
Analyst Charles Duncan comments, "Alexza reported 2Q12 earnings that were roughly in line with our and the Street’s expectations following a correction for restated share counts. Importantly, the company ended the quarter with $26.4MM in cash that we expect can fund operations into 2H13. We have modeled a $5MM milestone from Grupo Ferrer in 4Q12 for approval of the Adasuve MAA. We continue to view feedback from the agencies as positive regarding the safety and efficacy of Adasuve and anticipate approval in both the U.S. and EU in December. Our $12 price target is derived through an NPV valuation of projected Adasuve sales in the U.S. and the EU through 2022, discounted at 20%.
For an analyst ratings summary and ratings history on Alexza Pharma click here. For more ratings news on Alexza Pharma click here.
Shares of Alexza Pharma closed at $2.98 yesterday, with a 52 week range of $0.32-$4.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst Charles Duncan comments, "Alexza reported 2Q12 earnings that were roughly in line with our and the Street’s expectations following a correction for restated share counts. Importantly, the company ended the quarter with $26.4MM in cash that we expect can fund operations into 2H13. We have modeled a $5MM milestone from Grupo Ferrer in 4Q12 for approval of the Adasuve MAA. We continue to view feedback from the agencies as positive regarding the safety and efficacy of Adasuve and anticipate approval in both the U.S. and EU in December. Our $12 price target is derived through an NPV valuation of projected Adasuve sales in the U.S. and the EU through 2022, discounted at 20%.
For an analyst ratings summary and ratings history on Alexza Pharma click here. For more ratings news on Alexza Pharma click here.
Shares of Alexza Pharma closed at $2.98 yesterday, with a 52 week range of $0.32-$4.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
- Needham & Company Keeps Buy Rating on salesforce (CRM); Results 'Unspectacularly Solid'
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
JMP Securities, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
